Related Experiment Video
Updated: Jul 5, 2026

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
Published on: November 1, 2018
Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro
Mudassar Shahid1, Ahmed L Alaofi1, Mushtaq Ahmad Ansari2
1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abstract:
Concerns about the social and economic collapse, high mortality rates, and stress on the healthcare system are developing due to the coronavirus onslaught in the form of various species and their variants. In the recent past, infections brought on by coronaviruses severe acute respiratory syndrome coronaviruses (SARS-CoV and SARS-CoV-2) as well as middle east respiratory syndrome coronavirus (MERS-CoV) have been reported. There is a severe lack of medications to treat various coronavirus types including MERS-CoV which is hazard to public health due to its ability for pandemic spread by human-to-human transmission. Here, we utilized sinapic acid (SA) against papain-like protease (PLpro), a crucial enzyme involved in MERS-CoV replication, because phytomedicine derived from nature has less well-known negative effects. The thermal shift assay (TSA) was used in the current study to determine whether the drug interact with the recombinant MERS-CoV PLpro. Also, inhibition assay was conducted as the hydrolysis of fluorogenic peptide from the Z-RLRGG-AMC-peptide bond in the presence of SA to determine the level of inhibition of the MERS-CoV PLpro. To study the structural binding efficiency Autodock Vina was used to dock SA to the MERS-CoV PLpro and results were analyzed using PyMOL and Maestro Schrödinger programs. Our results show a convincing interaction between SA and the MERS protease, as SA reduced MERS-CoV PLpro in a dose-dependent way IC50 values of 68.58 μM (of SA). The TSA showed SA raised temperature of melting to 54.61 °C near IC50 and at approximately 2X IC50 concentration (111.5 μM) the Tm for SA + MERS-CoV PLpro was 59.72 °C. SA was docked to MERS-CoV PLpro to identify the binding site. SA bound to the blocking loop (BL2) region of MERS-CoV PLpro interacts with F268, E272, V275, and P249 residues of MERS-CoV PLpro. The effectiveness of protease inhibitors against MERS-CoV has been established and SA is already known for broad range biological activity including antiviral properties; it can be a suitable candidate for anti-MERS-CoV treatment.
Insights
Sinapic acid (SA) effectively inhibits MERS-CoV PLpro, a key enzyme in viral replication. This natural compound shows promise as a potential therapeutic agent against Middle East respiratory syndrome coronavirus (MERS-CoV) infections.
Area of Science:
- Biochemistry
- Virology
- Pharmacology
Background:
- Coronaviruses, including MERS-CoV, pose significant public health risks due to their pandemic potential and lack of effective treatments.
- Papain-like protease (PLpro) is essential for MERS-CoV replication, making it a critical target for antiviral drug development.
Purpose of the Study:
- To investigate the potential of sinapic acid (SA), a natural phytomedicine, as an inhibitor of MERS-CoV PLpro.
- To evaluate the interaction, inhibition, and binding site of SA with MERS-CoV PLpro.
Main Methods:
- Thermal Shift Assay (TSA) to assess drug-enzyme interaction.
- Enzyme inhibition assays to quantify the inhibitory effect of SA on MERS-CoV PLpro.
- Molecular docking using Autodock Vina, analyzed with PyMOL and Maestro Schrödinger, to determine the binding site and efficiency.
Main Results:
- Sinapic acid demonstrated a dose-dependent inhibition of MERS-CoV PLpro with an IC50 value of 68.58 μM.
- TSA indicated that SA increased the melting temperature of MERS-CoV PLpro, suggesting direct interaction.
- Molecular docking revealed that SA binds to the blocking loop (BL2) of MERS-CoV PLpro, interacting with specific amino acid residues.
Conclusions:
- Sinapic acid exhibits significant inhibitory activity against MERS-CoV PLpro.
- SA's interaction with MERS-CoV PLpro and its known antiviral properties suggest its potential as a therapeutic candidate for MERS-CoV infections.
More Related Videos
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
08:40Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
Related Concept Videos
Coronavirus
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly